Impax Laboratories plans to take on a substantial portfolio of generic drugs in a transaction that will be immediately accretive and allow for accelerating growth in the years to come.
Despite struggling mightily over the past couple of years, hedge funds still have a ton of assets under management.
Pfizer has announced that it has reached a definitive agreement to acquire Anacor Pharmaceuticals in a deal valued at more than $5 billion.
The top analyst upgrades, downgrades and initiations seen on Friday morning include Allergan, Lockheed Martin, Mylan, Nordstrom, Petrobras, NVIDIA, Western Digital.
The top analyst upgrades, downgrades and initiations seen Monday morning include Arcelor Mittal, Citigroup, 3M, NetApp and Union Pacific.
April 13, 2016: Here are two stocks trading with relatively heavy volume among 5 equities making new 52-week lows in Wednesday’s session. The day’s NYSE and Nasdaq winners led losers by about…
Paul Ausick April 12, 2016: Here are four stocks trading with relatively heavy volume among 17 equities making new 52-week lows in Tuesday’s session. The day’s NYSE winners led losers by about 3 to…
April 11, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. The day’s NYSE winners led losers by about 3-to-2. Nasdaq…
The breakup of the Pfizer-Allergan deal may only be a warning sign for both Apple and Google and any other company filtering money through foreign countries to avoid taxes, but the trend…
The Business Roundtable, the primary representatives of the CEOs of America's largest companies, made a statement about business combinations that involve tax inversions.
April 5, 2016: Here are four stocks trading with relatively heavy volume among 36 equities making new 52-week lows in Tuesday’s session. The day’s losers held a 2-to-1 advantage over gainers on…
At 24/7 Wall St., we like to show our readers the most widely held stocks by the hedge fund universe, as it gives a basic overview as to what the managers are…
Allergan reported better-than-expected fourth-quarter financial results before the markets opened on Monday.
Chris Lange Merrill Lynch has decided to add Pfizer as its new top pick for 2016. The firm reiterated a Buy rating with a $39 price target.
It's no big secret that hedge funds had a rocky third quarter. However that did not stop them from adding certain equities to their holdings in hopes of boosting their returns.
